The latest update is out from Vor Biopharma (VOR).
Vor Biopharma Inc. is experiencing a shift in its financial leadership, with CFO Nathan Jorgensen resigning to take on a new opportunity, effective June 21, 2024. His departure is amicable and unrelated to any internal disputes. The company has appointed Robert Ang as the interim principal financial officer and Amy Quinlan as the interim principal accounting officer, both stepping into their new roles on the same date. As the search for a new CFO is underway, stakeholders can rest assured that the interim appointments come with seasoned experience, with Ang already serving as President and CEO, and Quinlan bringing years of financial expertise from her previous tenure at TetraPhase Pharmaceuticals.
Find detailed analytics on VOR stock on TipRanks’ Stock Analysis page.
